| Literature DB >> 31538429 |
Jae Hyun Yoon1, Hee Joon Kim2, Chung Hwan Jun1, Sung Bum Cho3, Yochun Jung4, Sung Kyu Choi5.
Abstract
PURPOSE: Hepatic hydrothorax is a complication of decompensated liver cirrhosis that is difficult and complex to manage. Data concerning the optimal treatment method, other than liver transplantation, are limited. This study aimed to compare the clinical features and outcomes of patients treated with various modalities, while focusing on surgical management and pigtail drainage.Entities:
Keywords: Cirrhosis; drainage; hydrothorax; surgery
Mesh:
Year: 2019 PMID: 31538429 PMCID: PMC6753336 DOI: 10.3349/ymj.2019.60.10.944
Source DB: PubMed Journal: Yonsei Med J ISSN: 0513-5796 Impact factor: 2.759
Fig. 1Flowchart of patient enrollment and treatment. LT, liver transplantation.
Baseline Characteristics of Enrolled Patients
| Characteristics | Patients (n=41) |
|---|---|
| Age (yr) | 60.37±12.0 |
| Male | 33 (80.5) |
| BMI (kg/m2) | 22.99±3.22 |
| Etiology of liver cirrhosis | |
| Alcoholic/HBV/HCV/Others | 19 (46.3)/13 (31.7)/4 (9.8)/7 (17.1) |
| CTP score | 10.12±0.23 |
| A/B/C | 0 (0)/12 (29.3)/29 (70.7) |
| MELD score | 19.71±5.38 |
| Pleural fluid | |
| Right/Left/Both | 35 (85.4)/2 (4.9)/3 (7.3) |
| pH/Protein | 7.28±1.18/1.31±0.60 |
| LDH/Albumin/SPAG | 184.67±124.70/0.58±0.35/2.07±0.43 |
| Serum | |
| APRI score | 1.94±1.63 |
| Platelets (×103/μL) | 79.95±40.99 |
| Creatinine | 1.15±0.67 |
| Sodium | 135.54±4.88 |
| History of encephalopathy (>;Gr 2) | 12 (29.3) |
| Amount of ascites Gr 0/1/2/3 | 7 (17.1)/10 (24.4)/11 (26.8)/13 (31.7) |
| Follow-up duration (day) | 455.20±471.93 |
BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C virus; CTP, Child-Turcotte-Pugh; MELD, model for end-stage liver disease; LDH, lactate dehydrogenase; SPAG, serum-pleural fluid albumin gradient, APRI, aspartate aminotransferase to platelet ratio index; Gr, grade.
Values are presented as mean±standard deviation or n (%) unless otherwise indicated.
Clinical Characteristics and Outcomes of Patients Based on Treatment Modalities
| Serial thoracentesis (n=11) | Pigtail drainage (n=16) | Surgery (n=10) | Liver transplantation (n=4) | ||
|---|---|---|---|---|---|
| Cause of cirrhosis | 0.618 | ||||
| Alcohol | 4 (36.4) | 10 (62.5) | 4 (40.0) | 1 (25.0) | |
| HBV | 4 (36.4) | 3 (18.8) | 3 (30.0) | 3 (75.0) | |
| HCV | 2 (18.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Idiopathic | 1 (9.0) | 3 (18.8) | 3 (30.0) | 0 (0.0) | |
| HCC | 4 (36.4) | 3 (18.8) | 2 (20.0) | 0 (0.0) | 0.729 |
| Diuretics dose | |||||
| Furosemide (mg/day) | 72.0 | 55.0 | 57.8 | 90.0 | 0.373 |
| Spironolactone (mg/day) | 175.0 | 146.2 | 125.0 | 133.3 | 0.917 |
| Albumin (g/dL) | 2.94 | 2.60 | 2.49 | 2.55 | 0.462 |
| Total bilirubin (mg/dL) | 2.39 | 4.04 | 3.15 | 7.38 | 0.024 |
| PT (INR) | 1.45 | 1.77 | 1.64 | 2.01 | 0.013 |
| CTP (median, range) | 9.0 (8–12) | 11.0 (8–13) | 10.5 (9–12) | 10.5 (10–13) | 0.063 |
| MELD (median, range) | 17.0 (10–22) | 21.5 (14–32) | 18.0 (11–28) | 22.0 (17–29) | 0.017 |
| Survival duration (median, range) | 868.0 (49–1817) | 79.0 (15–1064) | 179.0 (48–980) | 601.5 (428–1270) | <0.001 |
| 12 months mortality (%) | 18.2 | 87.5 | 70.0 | 0.0 | <0.001 |
HBV, hepatitis B virus; HCV, hepatitis C virus; HCC, hepatocellular carcinoma; PT, prothrombin time; INR, international normalized ratio; CTP, Child-Turcotte-Pugh; MELD, model for end-stage liver disease.
Values are presented as median (range) or n (%) unless otherwise indicated.
Fig. 2Comparison of survival rates among treatment modalities by Kaplan-Meier analysis (serial thoracentesis vs. surgery, p=0.114; surgery vs. pigtail drainage, p=0.108; serial thoracentesis vs. pigtail drainage, p=0.001).
Comparison of Clinical Outcomes between Pigtail Drainage and Surgery Groups
| Surgery (n=10) | Pigtail (n=16) | ||
|---|---|---|---|
| Number of needle punctures for drainage/year | 9.3 | 23.5 | 0.161 |
| Thoracentesis | 0.9 | 18.8 | 0.016 |
| Paracentesis | 8.4 | 4.8 | 0.381 |
| Drainage amount (mL/day) | 125.5 | 288.0 | 0.320 |
| Occurrence of AKI | 5 (50.0) | 11 (68.8) | 0.548 |
| Occurrence of HRS | 3 (30.0) | 8 (50.0) | 0.432 |
| Cumulative overall survival (day) | 402.1 | 221.7 | 0.113 |
| Cut-off value of CTP | >10 | - | 0.038 |
| Cause of death | 6 | 14 | |
| Hepatic failure | 2 (33.3) | 6 (42.9) | |
| HRS | 2 (33.3) | 4 (28.6) | |
| Varix bleeding | 1 (16.7) | 1 (7.1) | |
| HCC progression | 1 (16.7) | 2 (14.3) | |
| Sepsis | - | 1 (7.1) | |
| Adverse events | Chest tube site oozing 1 | Pigtail site oozing 7 | |
| Delayed port site bleeding 1 | Pigtail site infection 1 | ||
| Incisional hernia 1 | Pigtail site pain* 4 | ||
| Pneumonia 1 | |||
| Urinary tract infection 1 | |||
| CRBI 1 | |||
| Perioperative mortality 0 | |||
| Recurrence of HH 2 |
AKI, acute kidney injury; HRS, hepatorenal syndrome; CTP, Child-Turcotte-Pugh; HRS, hepatorenal syndrome; HCC, hepatocellular carcinoma; CRBI, central catheter-related bacterial infection; HH, hepatic hydrothorax.
Values are presented as n (%) unless otherwise indicated.
*Defined as pain that required intervention.
Univariate and Multivariate Analyses on Survival Rates
| Factors | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| BMI <19 (kg/m2) | 6.6 (1.81–24.92) | 0.001 | 15.5 (3.23–74.58) | 0.001 |
| Serial thoracentesis | 0.41 (0.17–0.99) | 0.053 | ||
| Pigtail drainage | 4.24 (1.97–9.14) | <0.001 | 4.52 (2.02–10.15) | <0.001 |
| Surgery | 1.24 (0.50–3.08) | 0.639 | ||
| LT | 0.03 (0.00–1.93) | 0.103 | ||
| CTP score >10 | 3.6 (1.81–7.32) | <0.001 | 2.9 (1.22–7.14) | 0.021 |
| History of severe encephalopathy | 2.7 (1.33–5.44) | 0.004 | ||
| Ascites >Gr 1 | 2.2 (1.01–4.62) | 0.038 | ||
| MELD ≥16 | 2.6 (1.12–5.93) | 0.033 | ||
HR, hazard ratio; CI, confidence interval; BMI, body mass index; LT, liver transplantation; CTP, Child-Turcotte-Pugh; Gr, grade; MELD, model for end stage liver disease.